argenx SE reported $429.62M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
AstraZeneca USD 4.61B 4.46B Dec/2025
Galapagos EUR 44.42M 9.87M Dec/2025
Genmab DKK 208M 60M Dec/2025
GlaxoSmithKline GBP 2.68B 518M Dec/2025
GRIFOLS EUR 275.3M 9.7M Dec/2025
Hikma Pharmaceutical USD 288M 149M Dec/2025
Qiagen NV USD 153.88M 10.77M Dec/2025
UCB EUR 1.47B 193M Dec/2025